Finding and weighing primary sources — instead of just taking someone's word for it. You don't need a PhD; you need a handful of habits and a healthy skepticism.
This is educational information, not medical advice, and The Peptide University does not sell peptides, supplies, or supplements. Many compounds discussed here are sold as “research chemicals” and are not approved for human use outside of clinical trials. Laws vary by country, and nothing here is a recommendation to obtain or use anything. Talk to a qualified clinician about your own situation.
A primary source is the original research — the clinical trial, the lab study, the paper with methods and results. A secondary source summarizes it: a news article, a YouTube video, a forum post, a vendor's blog. Secondary sources are fine for finding studies, but you evaluate the claim by going to the primary source. The game is always: who actually measured this, and what did they measure?
Start with the abstract — the structured summary at the top. It tells you the population, what was done, and the headline result in about 250 words.
| Phase | Question it asks | Roughly how many people |
|---|---|---|
| Preclinical | Does it do anything in cells / animals? | No humans yet |
| Phase 1 | Is it safe? What dose is tolerated? | Tens |
| Phase 2 | Does it work, and at what dose? | Hundreds |
| Phase 3 | Does it work vs. standard care, at scale? | Thousands |
A compound with only preclinical or Phase 1 data is a long way from proven. That's not a reason to dismiss it — it's a reason to calibrate how confidently anyone (including you) should talk about it.
Five quick questions do most of the work:
Significant ≠ big. “Statistically significant” just means the result probably isn't random noise. It says nothing about whether the effect is large or useful. Always look at the actual numbers, not just the p-value.
Yes. Read the abstract, then the conclusion, then skim methods for sample size and controls. You'll understand more than you expect, and it gets easier fast.
They often do. Look at which are larger, better controlled, and more recent, and lean toward the weight of evidence rather than any single paper.
Preprints haven't been peer-reviewed yet. They can be valuable but should be read with extra caution — treat them as provisional.